Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ACMI - Accumed Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Cisco who wrote (631)	12/10/1997 8:04:00 AM
From: george	Respond to of 1894

Interesting story on stock rigging this morning: msnbc.com Also, the thin prep slides do work better than the conventional slides, but a cytologist still has to read the slides and so thin prep plus accumed make a good combination. George

To: Cisco who wrote (631)	12/10/1997 12:15:00 PM
From: Frank Buck	Read Replies (1) \| Respond to of 1894

Cisco and Others, Did you read the post by Gary Foote on Yahoo's ACMI Thread. He states message #35 of #39... "So thankyou guys from SI. Keep those postings going, your starting to get a fan club." Maybe The Motley Fool web will start an ACMI thread. Then AccuMed will really have broad coverage and exposure. Anyone know if there is any ACMI activity over there? As far as I know the BIG-three are SI, Yahoo and the Fool. Any other well recognized stock-forum group/threads? Anyone ever heard of a fan club-"stock-groupie"?... Me neither. Anyone from abroad out there? We would like to hear what you have heard in regard to the AccuMed/Leica International agreement and international community response to AccuMed's products.

To: Cisco who wrote (631)	12/10/1997 11:10:00 PM
From: Cisco	Read Replies (4) \| Respond to of 1894

To all, After watching the stock price of ACMI get bashed for no justifiable reason, perhaps it is time to reflect upon the situation if for no other reason than to maintain ones sanity. Lets consider similar companies in the field and after comparisons draw some conclusions for AccuMed. CYTYC Corp (CYTC) Sales for trailing twelve months $1.8M Market Cap $446,891,813 Price/Sales Ratio $22.27 EPS -1.46 (Market Cap)/Sales Ratio $24.42 Zacks' Wall Street Buy Recommendation 1.3 Neopath Inc (NPTH) Sales for trailing twelve months $9.14M Market Cap $208,495,500 Price/Sales Ratio $24.54 EPS -1.69 (Market Cap)/Sales Ratio $22.81 Zacks' Wall Street Buy Recommendation 3.0 Neuromedical Systems Inc (NSIX) Sales for trailing twelve months $8.14M Market Cap $100,769,500 Price/Sales Ratio $13.81 EPS -1.25 (Market Cap)/Sales Ratio $12.32 Zacks' Wall Street Buy Recommendation Not Rated Matritech Inc (NMPS) Sales for trailing twelve months $1.7M Market Cap $90,392,250 Price/Sales Ratio $48.97 EPS -0.39 (Market Cap)/Sales Ratio $53.17 Zacks' Wall Street Buy Recommendation 1.6 Chromovision Med Sys Inc (CVSN) Sales for trailing twelve months NONE Market Cap $160,753,125 Price/Sales Ratio NA EPS NA (Market Cap)/Sales Ratio NA Zacks' Wall Street Buy Recommendation Not Rated AccuMed International Inc (ACMI) Sales for trailing twelve months $13.2 Market Cap $33,223,125 Price/Sales Ratio $2.65 EPS -0.68 (Market Cap)/Sales Ratio $2.52 Zacks' Wall Street Buy Recommendation 1.0 Group Average Sales for trailing twelve months $8.42 Market Cap $173,420,885 Price/Sales Ratio $22.45 EPS -1.09 (Market Cap)/Sales Ratio $20.60 Zacks' Wall Street Buy Recommendation 1.7 What would be ACMI's share price if the company was valued at the group average for the following: Based Upon Share Price Price/Sales Ratio $13.08 (Market Cap)/Sales Ratio $12.01 But is AccuMed average? Consider the following: 1. Only AccuMed has a 1.0 buy recommendation. 2. AccuMed is one of only two in the group projecting to become profitable next year. 3. Only AccuMed has now been shown to produce an immediate cost benefit for the laboratories while increasing quality. 4. AccuMed has stated that the sales revenues growth for 1997 came primarily from "increased sales in the microbiology product line and the addition of the ESP product line." During the conference call the company now says interest in the cytopathology side of the company is taking off both nationally and internationally with systems being sold and contracts being signed. 5. Projections for Sales Revenues for 1997 is projected in the $20M range. At this rate of growth AccuMed's current Market Cap is probably less than what their 1998 Sales Revenues will be! No other company in this group can come close to saying that. 6. For icing on the cake, AccuMed has just announced that it has completed corporate consolidation which should reduce operating expenses next year by $2M. Can anyone explain to me why the stock is selling so low? Cisco